Evidence map›Paper›PMID 32551332›Full record

ArticleUrology practice2020

Routine Postoperative Hemoglobin Assessment Poorly PredictsTransfusion Requirement among Patients Undergoing Minimally Invasive Radical Prostatectomy.

Gregory T Chesnut, Nicole Benfante, David Barham, Lucas W Dean, Amy Tin, Daniel D Sjoberg, Peter T Scardino, James A Eastham, Behfar Ehdaie, Jonathan A Coleman and 3 more

Open access · greenAbstract read
In one paragraph

Article in Urology practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Gregory T ChesnutUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Nicole BenfanteUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
David BarhamUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Lucas W DeanUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Amy TinUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Daniel D SjobergUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Peter T ScardinoUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
James A EasthamUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Behfar EhdaieUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Jonathan A ColemanUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Timothy F DonahueUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Karim A TouijerUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Vincent P LaudoneUrology Service, Department of Surgery (GTC, NB, DB, LWD, PTS, JAE, BE, JAC, TFD, KAT, VPL), and Department of Epidemiology and Biostatistics (AT, DDS), Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

introductionAn advantage of minimally invasive radical prostatectomy over open surgery is decreased blood loss. At our institution hemoglobin is routinely checked 4 and 14 hours postoperatively. We assessed the relevance of this practice in a contemporary cohort undergoing minimally invasive radical prostatectomy.

methodsWe retrospectively reviewed data from patients undergoing laparoscopic or robotic radical prostatectomy at our institution between January 2010 and September 2018. We identified 3,631 patients with preoperative and postoperative hemoglobin values, and assessed the role of routine hemoglobin assessment in determining need for transfusion within 30 days. Medicare reimbursement rates for 2019 were used for cost analysis.

resultsOf 3,631 patients in our cohort 44 (1.2%) required transfusion. At 4 hours following surgery the median hemoglobin decrease was 8.0% (IQR 4.8 to 11.4) for patients who did not receive transfusion and 12.5% (9.5 to 19.2) for those who received transfusion. At 14 hours the median decrease was 14.2% (IQR 10.0 to 18.4) vs 33.1% (22.6 to 38.6). Routine hemoglobin assessment had no role in the decision to transfuse in 18 patients (41%). No patient was transfused based on 4-hour values alone. Omitting 1 hemoglobin assessment could have resulted in institutional savings of $37,000 during this period.

conclusionsAs transfusion following minimally invasive radical prostatectomy is rare, scheduled postoperative hemoglobin assessments in the absence of symptoms are unnecessary to recognize bleeding events. The largest hemoglobin difference between men who did vs did not receive transfusion was seen at 14 hours postoperatively. Thus, this single hemoglobin evaluation is sufficient.

Indexed as

postoperative carepostoperative complicationspostoperative hemorrhageprostatectomyprostatic neoplasms

Identifiers

PMID32551332
PMCPMC7301724
OpenAlexW2980967769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.